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ttp://dx.doi.org/10.1016/j.ajpath.2015.10.032Idiopathic pulmonary ﬁbrosis is a chronic, progressive ﬁbrotic disease with a poor prognosis. The
balance between transforming growth factor b1 and bone morphogenetic protein (BMP) signaling
plays an important role in tissue homeostasis, and alterations can result in pulmonary ﬁbrosis. We
hypothesized that multiple BMP accessory proteins may be responsible for maintaining this
balance in the lung. Using the bleomycin mouse model for ﬁbrosis, we examined an array of BMP
accessory proteins for changes in mRNA expression. We report signiﬁcant increases in mRNA
expression of gremlin 1, noggin, follistatin, and follistatin-like 1 (Fstl1), and signiﬁcant decreases
in mRNA expression of chordin, kielin/chordin-like protein, nephroblastoma overexpressed gene,
and BMP and activin membrane-bound inhibitor (BAMBI). Protein expression studies demon-
strated increased levels of noggin, BAMBI, and FSTL1 in the lungs of bleomycin-treated mice and
in the lungs of idiopathic pulmonary ﬁbrosis patients. Furthermore, we demonstrated that
transforming growth factor b stimulation resulted in increased expression of noggin, BAMBI, and
FSTL1 in human small airway epithelial cells. These results provide the ﬁrst evidence that multiple
BMP accessory proteins are altered in ﬁbrosis and may play a role in promoting ﬁbrotic injury.
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Disclosures: None declared.Idiopathic pulmonary ﬁbrosis (IPF) is a chronic, progressive
ﬁbrotic disease of unknown cause that is limited to the lungs.
Prognosis is extremely poor, with a median survival of 3 to 5
years after diagnosis. Transforming growth factor (TGF)-b1
has been shown to be a key mediator of ﬁbrosis in the lung.
Bone morphogenetic proteins (BMPs) are multifunctional
growth factors belonging to the TGF-b superfamily, and it
has been postulated that increased TGF-b1 signaling with a
concomitant reduction in BMPs is an important driver of
inﬂammation and ﬁbrosis.1 Moreover, there is growing evi-
dence that the interactions between members of the TGF-b
superfamily and the accessory proteins that modulate TGF-b
superfamily signaling are important in the development of an
array of inﬂammatory and ﬁbrotic diseases in the lung.2 It is
clear that members of the TGF-b superfamily are important
regulators of pulmonary homeostasis, and alterations in TGF-
b superfamily signaling contribute to the development ofstigative Pathology. Published by Elsevier Inc
Y-NC-ND license (http://creativecommons.orgpulmonary pathology. In particular, reductions in BMP
signaling are pivotal in the development of pulmonary hy-
pertension, pulmonary ﬁbrosis, and pulmonary inﬂamma-
tion.1,3,4 Furthermore, attenuated BMP signaling is a
recognized feature of inﬂammatory and ﬁbrotic conditions in
other organ systems, including the joints, kidneys, and
liver.5e7
In many disorders, reduced BMP signaling is associated
with a concomitant rise in TGF-b1/activin signaling. Thus,
balanced BMP and TGF-b1/activin signaling may be a.
/licenses/by-nc-nd/4.0).
BMP Accessory Proteins in Lung Fibrosiscrucial determinant of regeneration or repair after injury
versus maladaptive healing by ﬁbrosis. It has already been
shown that one BMP accessory protein, gremlin1 (a BMP
antagonist), is up-regulated in IPF.1 Gremlin1 is one of a
larger group of BMP accessory proteins, some of which also
bind to TGF-b1 or activin.8,9 We hypothesized that during
the disease process, the altered expression of a number of
different BMP accessory proteins may lead to an imbalance
in TGF-b1/BMP signaling, resulting in ﬁbrosis. To test this
hypothesis, we utilized a well-established mouse model of
ﬁbrosis in which intratracheal administration of bleomycin
provides an initial inﬂammatory response that heals by
ﬁbrosis, resembling the changes seen in human lung
injury.10 We examined the expression levels of a number of
BMP accessory proteins that are known to play a role in
lung diseases, are implicated in lung organogenesis, or are
known to be expressed in the lung. We selected key targets
to investigate further, looking at levels of protein expression
in ﬁbrotic mouse and human tissue and at the effects of
TGF-b1 induction on expression of these inhibitors in
human small airway epithelial cells (SAECs).
Materials and Methods
Animals
All procedures involving animals were approved by the Uni-
versity College Dublin Animal Research Ethics Committee and
licensed by the Department of Health and Children in accor-
dance with European Communities Regulations 2002
(Amendment of Cruelty to Animals Act 1876) and EU Direc-
tive 2010/63/EU. Speciﬁc pathogenefree adult male C57Bl/6J
wild-type mice (25 to 32 g at 10 to 15 weeks old) were used in
all experiments. Speciﬁc pathogenefree status was as deﬁned
in the Federation of Laboratory Animal Science Association
guidelines.11 All animals were exposed to the same 12:12-hour
lightedark cycle, and food and water were provided ad libitum.
Animals were housed singly in individually ventilated cages for
the duration of the study, maintaining speciﬁc pathogenefree
status. All mice used in the study were reared in the animal
facility from birth, and speciﬁc pathogenefree status was
according to the Federation of Laboratory Animal Science
Association guidelines.11
Bleomycin Mouse Model
Mice were randomly allocated by grab sampling to either a
saline (control) or bleomycin-inoculated group (n Z 12
per group). Mice were anesthetized by i.p. injection of 100
mg/kg ketamine (Vetalar; Pﬁzer, Sandwich, Kent, UK).
Intratracheal instillation was used to deliver either 1 U/kg of
bleomycin (Bleo-Kyowa; Kyowa Hakko Ltd, Slough, UK)
in 50 mL of normal saline or 50 mL of normal saline alone,
as described.12 In brief, once anesthetized, the mice were
suspended on a custom-made Perspex intubation stand
(made in-house) at an angle of 70 degrees by their frontThe American Journal of Pathology - ajp.amjpathol.orgincisors. The tongue was carefully pulled out and an oto-
scope (Welch Allyn 3.5 V Diagnostic Otoscope; Welch
Allyn Ltd, Meath, Ireland) with a pediatric tip was inserted
into the mouth until the epiglottis came into view. A metal
applicator was used to apply lidocaine jelly (Instillagel;
Farco-Pharma, Berlin, Germany) posterior to the epiglottis.
The otoscope was removed for 2 minutes, giving the lido-
caine time to anesthetize the vocal cords, and then reinserted
into the mouth, after which a 22-gauge catheter (Jelco,
Dublin, Ireland) mounted with a guide wire was passed
through the vocal cords. On conﬁrmation of correct place-
ment of the catheter, either bleomycin (1 U/kg in 50 mL of
normal saline) or 50 mL normal saline alone was instilled
down the intratracheal catheter. A Stepper Repetitive
Dispensing Pipette (Dymax, Kildington, Oxfordshire, UK)
was used to ensure that the exact volume was administered
to each mouse. The mice were extubated and allowed to
recover from anesthesia in a warming chamber. One mouse
from each group died during or immediately after the
inoculation procedure; thus, lungs from 11 animals were
available for analysis. Mice were housed individually after
inoculation in individually ventilated cages and observed
daily for adverse clinical signs, including the following:
appearance (eg, signs of dehydration, piloerection, lack of
grooming), body weight, behavior (eg, alterations in
mobility, vocalization), respiratory rate, and signs of pain. If
animals were deemed to be suffering more than moderate
adverse effects or had lost more than 20% of their initial
body weight, they were sacriﬁced by overdose of anesthesia
before the predeﬁned study time had elapsed.
Fourteen days after instillation, mice were sedated by
brief inhalation of 2% isoﬂurane (Vetﬂurance, Virbac,
Suffolk, UK) in oxygen vapor and then given an i.p. in-
jection of 60 mg/kg sodium pentobarbital (Rhône Merieux
Ltd, Harlow, UK) and 1000 IU/kg anticoagulated with
heparin (Leo Laboratories Ltd, Maidenhead, Berkshire,
UK). They were then returned to their cage and breathed
room air until conﬁrmation of an adequate depth of anes-
thesia by absence of response to tail compression; the
femoral artery was then incised and the mice sacriﬁced by
exsanguination. Post mortem a ligature was passed around
the right main bronchus to tie off the right lung. The right
lung was removed, snap-frozen in liquid nitrogen, weighed,
and then used for mRNA analysis. The remaining lung was
fully inﬂated via a tracheal cannula with ﬁxative [4% (w/v)
paraformaldehyde] at a pressure of 25 cm H2O for 30 mi-
nutes. After lung inﬂation, the left main bronchus was
ligated at the level of the hilum. The left lung was left in
ﬁxative for 24 hours. The volumes of the left lungs were
then measured by water displacement.13 Two lungs from the
bleomycin-inoculated group were punctured at the time of
isolation and thus could not be inﬂated; consequently, they
were not available for further histological study. One addi-
tional lung was excluded from each group for technical
reasons, leaving 10 and 8 lungs available for stereological
analysis in the control and bleomycin groups, respectively.601
Table 1 Antibodies Used in the Study
Primary Ab Company Code Technique Dilution
PO4 Smad 2 Cell Signaling Technologies 3107 WB (mouse) 1:500*
Total Smad2 Cell Signaling Technologies 3108 WB (mouse) 1:1000y
PO4 Smad 3 Cell Signaling Technologies 9520 WB (mouse) 1:500*
Total Smad 3 Cell Signaling Technologies 9513 WB (mouse) 1:1000*
PO4 Smad 1/5/8 Cell Signaling Technologies 95115 WB (mouse) 1:2000
z
Total Smad 1/5/8 Cell Signaling Technologies sc6031R WB (mouse) 1:200z
Noggin R&D Systems AF719 WB (mouse) 1:400*
IHC (mouse) 1:40x
Abcam Ab16054 IHC (human) 1.200
BAMBI R&D Systems AF2387 WB (mouse) 1:200*
IHC (mouse) 1:120x
R&D Systems AF921 IHC (human) 1.25
Follistatin-like 1 R&D Systems AF1738 WB (mouse) 1:500{
IHC (mouse) 1:90k
R&D Systems AF1694 IHC (human) 1.25
GAPDH Cell Signaling Technologies 2118S WB (mouse) 1:5000**
*Secondary antibody raised against rabbit, dilution 1:2000.
ySecondary antibody raised against mouse, dilution 1:2000.
zSecondary antibody raised against rabbit, dilution 1:5000.
xSecondary antibody raised against rabbit, dilution 1:150.
{Secondary antibody raised against goat, dilution 1:2000.
kSecondary antibody raised against goat, dilution 1:150.
**Secondary antibody raised against rabbit, dilution 1:10,000.
Murphy et alLung injury was quantiﬁed with stereological techniques
to determine the volume of the alveolar wall, including all of
the inﬂammatory cell inﬁltrate and ﬁbrotic extracellular
matrix within the gas exchange regions of the lungs,
as recommended by the joint American Thoracic Society/
European Respiratory Society policy statement on tissue
quantiﬁcation.14 After ﬁxation, the vertical axis of the lung
was identiﬁed and the lung was cut into 3-mm-thick slabs
perpendicular to the vertical axis of the lung, with a random
starting point chosen from within the ﬁrst 3 mm of lung.
This resulted in ﬁve to six slabs per left lung. These lung
slabs were then embedded in parafﬁn wax, using the char-
acteristic shape of each slab to maintain the vertical orien-
tation. Sections (5 mm thick) were cut from each slab until a
series of complete transverse sections (ie, completely sur-
rounded by pleural surface) had been obtained, and then one
was stained with hematoxylin and eosin for histological
assessment.
Multiple microscopic images of lung tissue were selected
from within each section by using a systematic random se-
lection strategy (Olympus BX61 motorized microscope with
an 20 objective; Olympus, Albertslund, Denmark). These
images were selected using the Computer-Assisted Stereo-
logical Tool system software (Visopharm Integrator System
version 2.9.11.0, Olympus), which controls movement of the
microscope stage so that the selection of the ﬁelds of view is
independent of the observer. The number of ﬁelds of view
taken from each section was proportional to the area of that
section. The computer program superimposed a 6  6-point
counting grid on each histological image. Because the
position of the sections within the lung, the microscopic ﬁelds602of view, and the position of the counting grid were randomly
selected, the probability of a point being superimposed on
lung tissue or airspace was directly proportional to the frac-
tion of the total volume of the lung occupied by that feature.
The observer who counted the number of points falling on
tissue or airspace was not informed of the treatment received
by that lung. Determination of the fraction of the lung
occupied by lung tissue (including all cells, extracellular
matrix, and inﬂammatory cells) and the volume of each lung
(measurement by water displacement) permitted calculation
of the total tissue volume in that lung.
Additional sections were stained with picrosirius red to
identify collagen. Sections (4 mm) were deparafﬁnized in
xylene, rehydrated, and treated with in 0.2% (v/v) aqueous
phosphomolybdic acid. Sections were stained using a 0.1%
(w/v) solution of Sirius Red (Sigma Aldrich, Dublin,
Ireland) in saturated aqueous picric acid (Sigma Aldrich)
for 90 minutes. Subsequently, sections were rinsed in 0.4%
(v/v) HCl solution and were then dehydrated in ascending
concentrations of ethanol, cleared with xylene, and cover-
slipped. Sections were viewed under polarized light, and 20
random images were acquired (10 objective) from each
lung, digitized, and analyzed using ImageJ software version
1.48v (NIH, Bethesda, MD; http://imagej.nih.gov/ij). The
signal in the green channel was segmented to allow mea-
surement of the percentage of the area of each image that
contained collagen, as identiﬁed by birefringence.
A second independent set of intratracheal inoculations of
saline (n Z 8) control or bleomycin (n Z 8) was then
completed, as previously described. Fourteen days after
saline or bleomcyin instillation, the left and right lungs wereajp.amjpathol.org - The American Journal of Pathology
Table 2 Applied Biosystems Gene Expression Assays
Gene Symbol Aliases Assay ID
Transforming growth factor, beta 1 Tgfb1 Mm01178820_m1
Collagen, type I, alpha 1 Col1a1 Cola-1, Mov-13 Mm00801666_g1
Connective tissue growth factor Ctgf Ccn2, Fisp12, Hcs24 Mm01192932_g1
BMP-binding endothelial regulator Bmper Cv-2, Crim3 Mm01175806_m1
Chordin Chrd Chd Mm00438203_m1
Gremlin 1 Grem1 Cktsf1b1, Drm, Ld Mm00488615_s1
Matrix gla protein Mgp Mglap Mm00485009_m1
Noggin Nog Mm01297833_s1
BMP and activin membrane-bound inhibitor Bambi Mm03053974_s1
Follistatin Fst Fs Mm00514982_m1
Follistatin-like 1 Fstl1 Fstl, TSC-36 Mm00433371_m1
Follistatin-like 3 Fstl3 Flrg Mm00473194_m1
Kielin/Chordin-like protein Kcp Crim2 Mm01159615_m1
Nephroblastoma overexpressed gene Nov Ccn3 Mm00456855_m1
Collagen, type I, alpha 1 COL1A1 OI4 Hs00164004_m1
Connective Tissue Growth Factor CTGF CCN2, HCS24, IGFBP8, NOV2 Hs01026927_g1
Noggin NOG SYM1, SYNS1 Hs00271352_s1
BMP and activin membrane bound inhibitor BAMBI NMA Hs01026927_g1
Follistatin-like 1 FSTL1 FRP, FSL1 Hs00907496_m1
BMP Accessory Proteins in Lung Fibrosisisolated post mortem and immediately snap-frozen. Protein
was extracted from the left lungs for use in enzyme-linked
immunosorbent assay and from corresponding right lungs
for use in Western blot analysis.
Enzyme-Linked Immunosorbent Assay
Protein suitable for enzyme-linked immunosorbent assay was
extracted from lung homogenized in phosphate-buffered saline
with added protease inhibitors and used in commercially
produced kits (R&D Systems, Abingdon, Oxfordshire, UK) to
quantify Bmp2, activin, and TGF-b1 concentrations.
Western Blot Analysis
Flash-frozen whole lung lysates were prepared in radio-
immunoprecipitation assay buffer (Merck Millipore, Bill-
erica, MA), homogenized by mechanical disruption
(Tissue Ruptor; Qiagen, Hilden, Germany), and sonicated
to ensure adequate lysis. Equal amounts of protein extract
were separated by SDS-PAGE, transferred onto poly-
vinylidene diﬂuoride membranes, and detected with
appropriate antibodies and secondary antibodies labeled
with horseradish peroxidase (Table 1). After incubation
with secondary antibody, proteins were visualized with an
enhanced chemiluminescent signal kit (Pierce ECL West-
ern Blotting Substrate; Thermo Fisher Scientiﬁc, Waltham,
MA). An identical amount of protein from a single standard
sample formed by pooling homogenate from lungs isolated
from mice in the saline control group was loaded onto each gel
to act as a loading and transfer control. Densitometric analysis
was performed using ImageJ software in two stages: the density
of the target band was normalized to the endogenous loading
control (GAPDH) for that sample, and the resultant value wasThe American Journal of Pathology - ajp.amjpathol.orgnormalized to the corresponding value for the pooled standard
sample on that gel.
Analysis of Gene Expression
Total mRNA was extracted from tissue and cell pellets were
snap-frozen in liquid nitrogen using the Qiagen RNeasy Mini-
kit (Qiagen) according to the manufacturer’s protocol. Total
RNA (1 mg) was reverse transcribed to cDNA using a Super-
Script II Reverse Transcriptase kit (Invitrogen, Carlsbad, CA).
Real-time PCR was performed on 384-well plates, and each
sample was measured in duplicate. An initial minus reverse
transcriptase reaction conﬁrmed that all RNA samples were free
of contaminating genomic DNA. Probes were ordered as
Assay-On-Demand Gene Expression Assays (Applied Bio-
systems, Foster City, CA) (Table 2). Reactions were performed
on the Applied Biosystems PRISM 7900 Sequence Detection
System (Applied Biosystems), and mRNA levels were deter-
mined using the comparative threshold method.15 We selected
BMP accessory proteins previously reported to play a role in
lung diseases, including gremlin 1, follistatin, noggin, BMP-
binding endothelial regulator (BMPER), and BMP and
activin membrane-bound inhibitor (BAMBI)1,16e18; BMP
accessory proteins implicated in lung organogenesis, including
follistatin-like 1 (FSTL1), matrix GLA protein (MGP), and
chordin in the bleomycin model of lung injury19e21; and BMP
accessory proteins known to be expressed in the normal lung:
follistatin-like 3 (FSTL3), nephroblastoma overexpressed gene
(NOV), and kielin/chordin-like protein (KCP).22,23
Immunostaining
Immunohistochemical localization of BAMBI, FSTL1, and
noggin was performed on parafﬁn-embedded lung sections603
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604from wild-type mice sacriﬁced 14 days after instillation
of bleomycin or saline, as previously described.24 Brieﬂy,
5-mmethick sections were cut from the surface of each
slice and mounted onto poly-1-lysineecoated glass slides
(Sigma, St. Louis, MO). Slides were baked for 18 hours at
37C, dewaxed, and hydrated. Endogenous peroxidase
activity was blocked by exposure to hydrogen peroxide
(0.3% v/v) in ethanol (70%). Antigen retrieval was un-
dertaken for 20 minutes in 10 mmol/L sodium citrate
buffer (pH 6.0) at a controlled temperature (95C) in a
water bath. Slides were washed in phosphate-buffered
saline and blocked in appropriate serum (10% diluted in
phosphate-buffered saline) for 1 hour. Tissue sections
were incubated in primary antibody (Table 1), diluted in
phosphate-buffered saline, and left for 18 hours at 4C in
humidiﬁed Petri dishes. Appropriate biotin-labeled sec-
ondary antibodies were used to detect speciﬁc binding
using streptavidin-linked horseradish peroxidase and
diaminobenzidine (Sigma Aldrich). The slides were then
counterstained with hematoxylin (Lennox Laboratory
Supplies, Dublin, Ireland) before being examined micro-
scopically on an Olympus BX61 microscope (40
objective).
Human Lung Tissue
Human IPF tissue was collected from explanted lungs at the
time of lung transplantation [n Z 6, all male, mean age 59.6
years (range 41 to 68 years)]. Control lung tissue was obtained
by taking tissue blocks from lobectomy samples removed
for surgical excision of cancer at a site remote from the tumor
(n Z 3, anonymized data). The protocols were approved by
the hospital ethics committee (Mater Misericordiae University
Hospital, Dublin, Ireland), and all patients gave written
informed consent. IPF was diagnosed according to the 2011
ofﬁcial American Thoracic Society/European Respiratory
Society/Japanese Respiratory Society/LatinAmericanThoracic
Association statement “Idiopathic Pulmonary Fibrosis:Figure 1 Treatment with intratracheal bleomycin results in lung damage
and ﬁbrosis. A: Absolute right lung weights 14 days after intratracheal
administration of bleomycin. B: Right lung weights relative to ﬁnal body
weight 14 days after intratracheal administration of bleomycin. C: Represen-
tative images of hematoxylin and eosinestained lungs 14 days after intra-
tracheal administration of bleomycin showing bronchocentric injury (black
arrow), small patches adjacent to the plural surface (gray arrow), perivascular
and peribronchial inﬂammatory cells, and signiﬁcant alveolar injury with loss
of airspace, thickening of alveolar walls, and intra-alveolar inﬂammatory cells
in bleomycin-treated mice compared with in normal saline controls. Bottom
two panels show polarized light images of picrosirius red staining. D: Ste-
reological analysis of volume of lung tissue plus inﬂammatory cells 14 days
after intratracheal administration of bleomycin. E and F: mRNA expression of
the TGF-beinducible genes Col1a1 and Ctgf after bleomycin instillation. Data
are expressed as medians (A and B) and medians  interquartile range (DeF).
mRNA values (E and F) are expressed as fold change relative to mean saline-
inoculated control value. *P < 0.05 and **P < 0.01, U-test. n Z 11 per
group (A, B, E, and F); n Z 10 and 8 for control and bleomycin groups,
respectively (D). TGF-b, transforming growth factor b.
ajp.amjpathol.org - The American Journal of Pathology
Table 3 mRNA Expression of a Panel of BMP-Related Proteins in Wild-Type Mouse Lung Lysates, 14 Days after Intratracheal Instillation of
Bleomycin
TGF-b superfamily ligand group Accessory protein
Relative mRNA expression
Control Bleomycin treated
BMP only BMPER29,30 1.1 (0.6e1.4) 1.1 (0.7e1.3)
Chordin31 1.0 (0.8e1.2) 0.7 (0.5e1.1)*
Gremlin 132 1.1 (0.9e1.2) 12.6 (4.0e15.0)**
MGP33,34 1.0 (0.9e1.2) 1.3 (1.1e1.5)
Noggin35 0.9 (0.8e1.4) 1.5 (1.3e2.5)*
BMP and TGF-b/activin BAMBI9 1.0 (0.5e1.8) 0.1 (0.1e0.3)*
Follistatin8,36,37 1.1 (0.9e1.2) 6.5 (2.2e10.0)**
Follistatin-like 122,38,39 1.0 (0.9e1.3) 1.7 (1.3e2.0)**
Follistatin-like 322,40 1.0 (0.9e1.1) 0.9 (0.7e1.4)
KCP41e43 1.0 (0.8e1.5) 0.5 (0.3e0.6)**
NOV44 0.9 (0.8e1.2) 0.3 (0.2e0.4)**
Data are expressed as medians  interquartile range. Values are displayed as fold change relative to mean saline-inoculated control value. nZ 11 per group,
except for NOV, where n Z 10 for technical reasons.
*P < 0.05, **P < 0.01, U-test.
BMP Accessory Proteins in Lung FibrosisEvidence-Based Guidelines for Diagnosis and Manage-
ment.”25 Human tissue slides were stained on the Auto-
mated Dako Autostainer Link 48 (DakoCytomation Ireland
Ltd, Galway, Ireland) by using Dako antigen retrieval
buffer at pH 6.0 and EnVision Flex and LSABþ kits
(DakoCytomation Ireland Ltd).
Cell Culture Experiments
Cell culture experiments were performed with primary human
SAECs (Lonza, Basel, Switzerland) obtained from a 19-year-
old male nonsmoker. The SAECs were maintained in SAEC
growth medium (Lonza) at 37C in 5% CO2. All cells used in
these experiments were between passages 5 and 7 and were
routinely checked to conﬁrm absence of Mycoplasma
contamination by the MycoAlert assay (Cambrex Bioscience,
Nottingham, UK). SAECs were seeded onto 12-well plates
and grown until 80% conﬂuency. The medium was changed,
and the cells were either treated with 10 ng/mL TGF-b1 (R&D
Systems) in 4 mmol/L HCl containing 1% bovine serum
albumin or treated with vehicle alone (sterile 4 mmol/L HCl
containing 1% bovine serum albumin), as a control. After 72
hours of treatment, the cells were lysed and RNA extracted for
further analysis, as described above in Analysis of Gene
Expression. These conditions were chosen because they had
previously been shown to lead to the expression of markers of
epithelial-mesenchymal transition in these cells by RT-qPCR
(cadherin 1, vimentin, and a-smooth muscle actin) and
Western blot analysis with densitometry (cadherin 1, zona
occludens 1, vimentin, and a-smooth muscle actin).26
Statistical Analysis
Normally distributed data are reported as means  SEM,
whereas non-normally distributed data are presented as
medians  interquartile range. For normally distributedThe American Journal of Pathology - ajp.amjpathol.orgdata, statistical signiﬁcance of differences between two
group means was determined with t-tests. For non-normally
distributed data, statistical signiﬁcance was determined by
using the U-Test (unpaired test); P values were computed
using the exact permutation method. P < 0.05 was accepted
as statistically signiﬁcant.Results
Treatment with Intratracheal Bleomycin Results in
Lung Fibrosis
At the start of the study there was no signiﬁcant difference in
body weight between groups: median weight was 29.0 g
(27.5 to 30.5 g) in the control group (n Z 11) and 29.0 g
(27.8 to 30.3 g) in the bleomycin-treated group (n Z 11).
Intratracheal bleomycin treatment led to signiﬁcant weight
loss (3.75 g  0.63 g) compared with saline-inoculated
mice (0.45 g  0.36 g; P < 0.01). Two of the
bleomycin-treated animals had to be sacriﬁced humanely
before the 14-day period after instillation had elapsed because
of excessive (>20%) weight loss (on day 7 and day 11).
In the second group of mice used to investigate protein
levels of BMP accessory proteins, all mice survived the course
of the study, although the bleomycin-treated mice still had
signiﬁcant weight loss (3.80 g  0.73 g) compared with
the saline-inoculated mice (0.25 g  0.18 g; P < 0.001).
Median lung weight was signiﬁcantly increased in ani-
mals treated with bleomycin compared with in those
treated with saline, both when expressed as absolute lung
weight and when lung weight was corrected for the ﬁnal
body weight (Figure 1, A and B). This was replicated in
the later 14-day study.
Histological examination of the lungs (Figure 1C)
demonstrated bronchocentric injury, small patches adjacent
to the plural surface, perivascular and peribronchial605
Figure 2 Treatment with intratracheal bleomy-
cin results in changes in TGF-b1 and BMP expression
and signaling. A: Concentrations of BMP2, TGF-b,
and activin proteins measured by enzyme-linked
immunosorbent assay in lung lysates 14 days after
intratracheal administration of bleomycin compared
with in saline-inoculated controls. B: Representative
Western blot showing PO4 Smad2, total Smad2, and
GAPDH expression and densitometry analysis of the
ratio of PO4Smad2 to total Smad2. C: Representative
Western blot showing PO4 Smad1/5/8, total Smad1/
5/8, and GAPDH expression and densitometry anal-
ysis of the ratio of PO4Smad1/5/8 to total Smad1/5/
8. Data expressed as medians  interquartile range
(B and C). n Z 8 per group (AeC). *P < 0.05,
**P < 0.01, U-test. B, bleomycin-treated; BMP,
bone morphogenetic protein; C, saline control; PS,
pooled sample; TGF-b, transforming growth factor b.
Murphy et alinﬂammatory cells, and signiﬁcant alveolar injury with
loss of airspace, thickening of alveolar walls, and intra-
alveolar inﬂammatory cells in the bleomycin-treated
mice compared with in the normal saline controls,
which was consistent with ﬁbrotic injury. Stereological
analysis conﬁrmed that the bleomycin-treated mice had
an increase in the total volume of lung tissue, reﬂecting
inﬂammatory cell inﬁltration and ﬁbrotic matrix deposi-
tion (Figure 1D). Picrosirius red staining showed
increased collagen in sections from bleomycin-inoculated
lungs when compared with saline controls (Figure 1C).
The mean area of collagen identiﬁed by birefringence
in picrosirius redestained sections was signiﬁcantly
(P < 0.01) elevated in the bleomycin-injured lungs
(3.84  0.51%, n Z 8) when compared with saline-
inoculated lungs (3.00  0.45%, n Z 7).
Collagen accumulation is a major feature of ﬁbrosis,
and one of the most important mediators of collagen
synthesis is TGF-b1.27,28 We therefore investigated the
levels of expression of two TGF-b1eregulated genes,
Col1a1 and Ctgf, which are characteristically elevated in
the bleomycin-induced pulmonary ﬁbrosis model. Col1a1
and Ctgf were signiﬁcantly increased in the bleomycin-
treated mice (Figure 1, E and F), which was in keeping
with an established proﬁbrotic state. Taken together with606the histological ﬁndings, these results show a pattern
typical of bleomycin-induced ﬁbrosis.
The mRNA Expression of BMP-Related Signaling
Molecules Is Altered in Fibrotic Lungs
To investigate the expression of BMP accessory proteins
in ﬁbrosis and TGF-b1/BMP signaling, we examined the
mRNA expression of a panel of extracellular BMPe
related signaling molecules (Table 3). With regard to
RNA of the BMP accessory proteins known to interact
with BMP alone, gremlin 1 and noggin mRNA was
signiﬁcantly up-regulated after bleomycin treatment
compared with saline-inoculated controls, chordin mRNA
expression was signiﬁcantly decreased in bleomycin-
treated mice, and there was no signiﬁcant difference in
expression of Bmper and Mgp mRNA (Table 3). With
regard to the RNA of the BMP accessory proteins that
predominantly interact with BMP and TGF-b1/actin,
follistatin and Fstl1 mRNA were signiﬁcantly up-
regulated in bleomycin-treated mice, whereas Bambi,
KCP, and Nov mRNA were signiﬁcantly down-regulated
in bleomycin-treated mice. There was no change in
FSTL3 mRNA in the bleomycin-treated mice compared
with in the saline controls.ajp.amjpathol.org - The American Journal of Pathology
Figure 3 Investigation of noggin protein levels
in intratracheal bleomycin-treated lungs. A: Locali-
zation of noggin by immunohistochemical staining.
Upper six microscopic images (40 and 60 ob-
jectives) show noggin present in the epithelial cells
of airways and alveolar macrophages in control and
bleomycin-treated lungs and in the alveolar cells of
bleomycin-treated animals. Bottom panels present
concentration-matched nonimmune goat IgG
showing absence of staining. Blue arrow indicates
macrophage; green arrow, bronchial epithelium;
yellow arrow, pneumocytes; and red arrow, ﬁbro-
blasts. B: Representative Western blot showing
expression of noggin protein in lungs 14 days after
intratracheal administration of bleomycin compared
with saline-inoculated controls. C: Densitometry
analysis of noggin protein expression normalized to
GAPDH. Data are expressed as medians  inter-
quartile range (C). nZ 8 per group (C). *P < 0.05,
U-test. B, bleomycin-treated; C, saline control; Obj,
objective; PS, pooled sample.
BMP Accessory Proteins in Lung FibrosisThe Protein Expression of BMP-Related Signaling
Molecules Is Altered in Murine Fibrotic Lungs
To further investigate the BMP-related signaling molecules in
ﬁbrosis, we selected three targets for examination of protein
changes: noggin, BAMBI, and FSTL1. In a separate series of
experiments, we collected lungs from bleoycin-inoculated
mice (n Z 8) and saline-inoculated mice (n Z 8) and
extracted protein suitable for Western blot analysis and
enzyme-linked immunosorbent assay. Protein levels of TGF-
b1 were signiﬁcantly increased in the bleomycin-treated miceThe American Journal of Pathology - ajp.amjpathol.orgcompared with in the controls (Figure 2A). Concomitant with
this, we found increased levels of activin, which is also
implicated in ﬁbrotic disease,45 and reduced levels of BMP2
(Figure 2A). TGF-b1 and BMP signal through a heteromeric
cell surface serine/threonine kinase complex,46 resulting in the
receptor-mediated phosphorylation and activation of either
Smad2/3 (TGF-b1 and activin) or Smad1/5/8 (BMPs) tran-
scription factors and alterations in gene transcription. Corre-
sponding to increased levels of TGFB1 and activin, we found
that the ratio of phospho-Smad2 to total Smad2 was signiﬁ-
cantly increased in the bleomycin-treated lungs (Figure 2B).607
Table 4 Comparison of Cellular Location of Noggin, BAMBI, and FSTL1 in Human Lung Specimens and Saline-Inoculated (Control) and
Bleomycin-Inoculated Mouse Lungs
Cellular location
Noggin BAMBI FSTL1
Cont IPF C Bleo Cont IPF C Bleo Cont IPF C Bleo
Macrophages þ þ þ þ þ þ þ þ þþ þ þ þ
Bronchial epithelium þ þ þ þ þ þ þ þ þþ þ þ þ
Endothelial cells þ þ  þ  þ   þþ þ  
Smooth muscle þ þ    þ   þþ þ þ þ
Pneumocytes*  þ þ þþ  þ þ   þ þ þ
Inﬂammatory cells NA þ NA þ NA þ NA  NA þ NA 
Fibroblasts NA þ NA þ NA þ NA þ/ NA þ NA þ/
Honeycomb metaplastic epithelium NA þ NA NA NA þ NA NA NA þ NA NA
*Type 2 pneumocyte hyperplasia in IPF and bleomycin-injured lungs.
þ, present; , absent; Bleo, bleomycin-inoculated mice; C, saline-inoculated control mice; Cont, control human lung tissue; IPF, lung tissue from IPF lungs;
NA, not applicable.
Murphy et alHowever, there was no signiﬁcant difference in the ratio of
phospho-Smad3 to total Smad3 (data not shown). The ratio of
phospho-Smad 1/5/8 to total Smad 1/5/8 was signiﬁcantly
reduced after bleomycin treatment (Figure 2C), which is
consistent with reduced BMP signaling.
Noggin was detected in macrophages and bronchial
epithelial cells of control and bleomycin-treated lungs, type II
pneumocytes, inﬂammatory cells, and ﬁbroblasts of
bleomycin-treated lungs (Figure 3A, Table 4). In addition,
noggin was detected in the vascular endothelium of the
bleomycin-treated lungs (Supplemental Figure S1). There was
no staining in specimens stained with nonimmune goat IgG
instead of primary antibody (Figure 3A). Immunohistochem-
ical analysis showed more intense staining of protein in
bleomycin-treated lungs (Table 4). Western blot analysis
detected a single band at the expected molecular weight of
noggin (Figure 3B), which showed decreased levels of noggin
in the bleomycin-treated lungs (Figure 3C).
BAMBI was localized in the macrophages and bronchial
epithelium of control and bleomycin-treated lungs. Occa-
sional ﬁbroblasts positive for BAMBI were also seen in
bleomycin-treated lungs (Figure 4A, Table 4). There was no
staining in specimens when nonimmune goat IgG was
substituted for primary antibody at the same concentration
(Figure 4A). Western blot analysis visualized BAMBI as two
bands, which is consistent with N-glycosylation (Figure 4B).
The higher-molecular-weight band, which represents the
glycosylated form of protein, was seen to be more highly
expressed in bleomycin-treated mice (Figure 4C), whereas
the lower molecular weight band was only detected in saline-
inoculated mice.
FSTL1 was localized in the macrophages, bronchial
epithelium, and smooth muscle cells of control and
bleomycin-treated lungs, but in type II pneumocytes and
occasional ﬁbroblasts of just the bleomycin-treated lungs
(Figure 5A, Table 4). There was no staining in sections in
which the same concentration of nonimmune goat IgG
was used instead of primary antibody (Figure 5A).
Immunohistochemical analysis showed more intense608staining in bleomycin-treated lungs compared with in
saline controls (Figure 5). FSTL1 is a 46-kDa protein that
appeared as a doublet on immunoblot because of glyco-
sylation (Figure 5B), which is consistent with previous
reports.47 Densitometry demonstrated a signiﬁcant in-
crease of expression of FSTL1 protein (both bands) in the
bleomycin-treated lungs (Figure 5C).
Noggin, FSTL1, and BAMBI Are Expressed in Human
Fibrotic Disease
To see whether alterations of BMP accessory proteins occur
in humans with ﬁbrotic lung disease, we used sections from
patients with IPF (nZ 6) and control lung (nZ 3). Noggin,
BAMBI, and FSTL1 were all present in macrophages, type
II pneumocytes, endothelial cells, and smooth muscle cells
of both healthy lungs and those for individuals with IPF
(Table 4 and Figure 6). In addition, these proteins were also
present in areas of ﬁbroblastic focus and honeycomb
metaplastic epithelium, which is characteristic of ﬁbrotic
lung disease.
TGFB1 Stimulation Increases the Expression of Noggin,
FSTL1, and BAMBI mRNA Expression in Human SAECs
TGFB1 is known to regulate many BMP accessory pro-
teins. This means that there may be a feedforward loop
whereby increased BMP antagonism results in increased
TGFB1 signaling, which in turn increases levels of BMP
accessory proteins further. We therefore tested whether
TGFB1 induced changes in the expression of noggin,
FSTL1, and BAMBI by using human SAECs. To conﬁrm
TGF-b1einduced responses in the SAECs, we ﬁrst
measured mRNA expression levels of the TGF-
b1einducible genes COL1A1 and CTGF, and demon-
strated signiﬁcant increases of both genes (twofold and
threefold, respectively). Further measurement of the BMP
accessory proteins noggin, FSTL1, and BAMBI
(Figure 7), demonstrated that mRNA expression wasajp.amjpathol.org - The American Journal of Pathology
Figure 4 Investigation of BAMBI protein
levels in intratracheal bleomycin-treated lungs.
A: Localization of BAMBI by immunohistochem-
ical staining. Upper six microscopic images (40
and 60 objectives) show BAMBI present in the
epithelial cells of airways and alveolar macro-
phages in control and bleomycin-treated lungs
and in the alveolar cells of bleomycin-treated
animals. Bottom panels present concentration-
matched nonimmune goat IgG showing absence
of staining. Blue arrow indicates macrophage;
green arrow, bronchial epithelium; red arrow,
ﬁbroblasts. B: Representative Western blot
showing expression of BAMBI protein in lungs 14
days after intratracheal administration of bleo-
mycin compared with saline-inoculated controls.
C: Densitometry analysis of BAMBI protein
expression normalized to GAPDH. Data are
expressed as medians  interquartile range (C).
n Z 8 per group (C). *P < 0.05, U-test. B,
bleomycin-treated; C, saline control; Obj,
objective; PS, pooled sample.
BMP Accessory Proteins in Lung Fibrosissigniﬁcantly increased for all three compared with in
nontreated controls. These ﬁndings show that for human
SAECs, increases in TGF-b1 stimulate concomitant in-
creases in expression of BMP accessory proteins.Discussion
The TGF-b1/BMP signaling cascade plays an important
role in maintaining tissue homeostasis in the lung.The American Journal of Pathology - ajp.amjpathol.orgDysregulation of this pathway, increased TGF-b1 and
activin signaling, leads to ﬁbrosis through increased
collagen production, epithelial-mesenchymal transition,
and ﬁbrotic laydown, whereas increased BMP signaling
can reverse ﬁbrotic change.1,48 There is signiﬁcant
crosstalk between the members of the TGF-b super-
family, and alterations in expression of BMP accessory
proteins are emerging as an important component of
pulmonary pathology.2,49 Although work has been per-
formed to look at alterations in certain speciﬁc BMP609
Figure 5 Investigation of levels of FSTL1 pro-
tein in intratracheal bleomycin-treated lungs.
A: Localization of FSTL1 by immunohistochemical
staining. Upper six microscopic images (40 and
60 objectives) show FSTL1 present in the
epithelial cells of airways and alveolar macro-
phages in control and bleomycin-treated lungs,
and in the alveolar cells of bleomycin-treated an-
imals. Bottom panels: Concentration-matched
nonimmune goat IgG showing absence of stain-
ing. Blue arrow indicates macrophage; green
arrow, bronchial epithelium; yellow arrow, pneu-
mocytes; red arrow, ﬁbroblasts; black arrow;
smooth muscle cells. B: Representative Western
blot showing expression of FSTL1 protein in lungs
14 days after intratracheal bleomycin compared to
saline inoculate controls. C: Densitometry analysis
of FSTL1 protein expression normalized to GAPDH.
Data are expressed as medians  interquartile
range (C). nZ 8 per group (C). *P < 0.05, U-test.
B, bleomycin treated; C, saline control; Obj,
objective; PS, pooled sample.
Murphy et alaccessory proteins in lung ﬁbrosis,1 this is the ﬁrst study
to examine the expression of multiple BMP accessory
proteins during the ﬁbrotic process.
Bleomycin-Induced Pulmonary Fibrosis
Bleomycin-treated mice were used as a model for ﬁbrosis as
they have previously been shown to model changes seen in
human lung injury.10 The mice used in these experiments
were conﬁrmed to have an established proﬁbrotic state as
they had characteristics consistent with ﬁbrosis: increased610weight and volume of lungs (Figure 1, A and B),50e52
bronchiocentric ﬁbrotic change, thickening of alveolar
walls, obliteration of airspace and inﬂammatory cell inﬁltrates
(Figure 1C),53 increased volume of lung tissue because of
inﬂammatory cell inﬁltrates, ﬁbrotic matrix deposition
(Figure 1D), and increased collagen as identiﬁed by picrosirius
redeinduced birefringence. In addition, the bleomycin-
inoculated lungs showed increased levels of TGF-b,
increased phosphorylation of SMAD2, and increased mRNA
expression of the TGF-b1einducible proﬁbrotic genesCol1a1
and Ctgf (Figure 2),27,28 all of which are compatible with theajp.amjpathol.org - The American Journal of Pathology
Figure 6 Immunohistochemical localization of bone morphogenetic protein accessory proteins in human lungs. Noggin, BAMBI, and FSTL1 are all present
in macrophages and pneumocytes in the normal lung. In IPF lungs, all three proteins are present in macrophages, type II pneumocytes, inﬂammatory
aggregates, and metaplastic epithelia. Black arrow indicates macrophage; long arrow, alveolar macrophages; star, bronchial epithelium; arrowhead,
endothelial cells; red arrow, ﬁbroblasts of the ﬁbroblastic focus; short, thick black arrow, overlying type II pneumocyte hyperplasia; blue arrow, indicates
inﬂammatory aggregate. All images were acquired on a 20 objective. Scale bar Z 200 mm. E, metaplastic epithelium in honeycomb areas; IPF, idiopathic
pulmonary ﬁbrosis; V, vessel.
BMP Accessory Proteins in Lung Fibrosisincreased TGFB signaling typically observed during the
development of lung ﬁbrosis.
Altered BMP Accessory Protein Expression in Fibrotic
Lungs
Initial investigation of BMP accessory proteins found alter-
ations in the mRNA expression of multiple genes in the
ﬁbrotic lungs: Gremlin 1, Noggin, Follistatin, and Fstl1 were
all signiﬁcantly up-regulated; whereas Chordin, Kcp, Nov, and
Bambi were signiﬁcantly down-regulated (Table 3). Although
levels of mRNA expression can give some indication as to
changes occurring during ﬁbrosis, post-translational
modiﬁcations are an important mechanism regulating
expression of many proteins. We therefore looked in
greater detail at the protein expression of three targets:
noggin, BAMBI, and FSTL1. These BMP accessory
proteins were chosen because this was the ﬁrst time they
had been examined in a model of ﬁbrotic lung disease,
although the expression of each had been implicated
previously in ﬁbrosis in other organs.54,55 Noggin is an
example of a protein acting solely as a BMP-binding
protein; it inhibits the actions of BMP2, 4, and 7.35,56 In
addition to binding BMP2 and 4, BAMBI and FSTL1 also
affected TGF-b1/activin binding9,39 and had opposingThe American Journal of Pathology - ajp.amjpathol.orgchanges in mRNA expression, decreased and increased,
respectively.
Alterations in Expression of Noggin Protein
In the bleomycin mouse model, noggin staining was more
extensive in immunohistochemical analysis, which is
consistent with increased mRNA expression (Figure 3A);
however, Western blot analysis suggested that the expression
was decreased in bleomycin-treated mice compared with in
controls (Figure 3C). This difference between the immuno-
histochemical and Western blot analyses may be explained
by a number of potential mechanisms. First, apparent
changes in intensity on immunohistochemical analysis are
often difﬁcult to judge unless they are very large (presence or
absence), so this technique primarily gives information about
cellular location rather than concentration of a protein. Sec-
ond, increased expression in speciﬁc subpopulations of cells
within the lungmight lead to increased intensity of staining in
those cells. However, Western blot analysis provides an
index of the concentration averaged throughout all cells
within the lung. Thus, noggin is diluted by protein extracted
from cells that do not express it and by extracellular soluble
proteins. If other such soluble proteins were increased in the
ﬁbrotic lung, because of either proliferation or inﬁltration, the611
Figure 7 mRNA expression of noggin, BAMBI,
and FSTL1 in SAECs stimulated with transforming
growth factor b (TGF-b) or vehicle. Data are
expressed as medians interquartile range. Values
are normalized to 18s rRNA and expressed as fold
change relative to vehicle-treated controls. nZ 12
per group. *P < 0.05, **P < 0.01 compared with
vehicle-treated SAEC control (U-test). SAEC, small
airway epithelial cell; TGF-b, transforming growth
factor b.
Murphy et aleffect would be to reduce noggin levels detected by Western
blot analysis. A second possibility is selective loss of noggin
during protein extraction for Western blot analysis. For
example, this might occur because of very avid binding of
noggin to the cellular glycocalyx on cell surfaces.
Noggin is glycosylated, and matrix binding is a property
of such proteins. It has been shown previously that noggin
binds to the glycocalyx and that this bound protein is not
effectively extracted by standard tissue lysis techniques.
Moreover, noggin bound to the glycocalyx remains an
effective blocker of BMP signaling.57 Noggin bound to the
cellular glycocalyx in such a manner would be stained in
ﬁxed sections and would appear in a cellular distribution.
Finally, nonspeciﬁc sticking of the noggin antibody to the
tissue section must always be considered in these circum-
stances. However, nonimmune immunoglobulin of the same
type that was prepared from the same species did not produce
such nonspeciﬁc staining. Furthermore, we used the same anti-
noggin antibody in both Western blot and immunohisto-
chemical analysis, and it identiﬁed a single band at the correct
molecular weight. Further work will be required to determine
the exact modulating role of noggin in BMP signaling in
pulmonary ﬁbrosis and thus in inﬂuencing the abnormal TGF-
b1BMP balance observed in the ﬁbrotic process.
Of note, our ﬁndings in human SAECs demonstrate that
TGF-b1 drives an increase in noggin that could inhibit BMP
and potentiate the proﬁbrotic action of TGF-b1. This represents
a feedforward mechanism that could drive ﬁbrosis. Noggin acts
as a BMP antagonist by binding directly to BMP molecules,
preventing BMP from binding to the BMP receptor.56 This
leads to a reduction in signaling through the Smad1/5/8
pathway and to a concomitant increase in Smad2/3 pathway.
Any local increase in noggin protein in the bleomycin-treated
lungs may therefore repress the BMP signaling pathway and
boost the TGF-b1 signaling pathway, thus increasing ﬁbrosis.
Moreover, the ﬁnding in SAECs that nogginmRNA expression
was increased by stimulation with TGF-b1 (Figure 7) suggests
that ﬁbrosis will be further enhanced, favoring maladaptive
ﬁbrotic healing rather than repair.Alterations in BAMBI Protein Expression
In the bleomycin mouse model, BAMBI protein was
more highly expressed, as demonstrated by both612immunohistochemical and Western blot analysis (Figure 4),
in contrast to the lower levels of mRNA expression. A
similar opposing ﬁnding has been seen in liver cells, in which
low levels of mRNA expression correlated with high protein
levels in primary human hepatocytes.55 On the Western blot
there were two bands: the heavier band was present in both
the control and bleomycin-treated mice, although it was more
highly expressed in the bleomycin-treated mice. The smaller
band was present only in the control mice. It is possible that
BAMBI protein becomes glycosylated and membrane bound
during ﬁbrotic lung injury, causing the protein to become
more stable, with less degradation. So although mRNA
expression decreases, and there is less protein production and
the overall level of stable glycosylated protein is increased by
post-translational modiﬁcations. This may be due to the ef-
fects of post-translational glycosylation, as the heavier, more
glycosylated form of BAMBI had higher expression in the
bleomycin-treated mice (Figure 4C), and likewise in the liver,
primary human hepatocytes produced a glycosylated form of
BAMBI.55 BAMBI is a pseudoreceptor, with an extracellular
domain similar to that of type I TGF-b1 receptors but no
intracellular kinase domain. It acts as a decoy receptor and
has been reported to antagonize both the BMP and TGF-b1/
activin signaling pathways by preventing the formation of
active receptor complexes on binding.9 In cardiac and hepatic
cells, BAMBI protects against ﬁbrosis through blocking of
TGF-b signaling.55,58 This suggests that the increased levels
of BAMBI protein found in both the bleomycin mouse model
and IPF patients may be a protective measure to block
excessive TGF-b1 signaling and lessen pathological ﬁbrosis.Alterations in FSTL1 Protein Expression
In the bleomycin mouse model, FSTL1 protein was up-
regulated, as seen by immunohistochemical analysis and
Western blot analysis consistent with the mRNA expression
(Figure 4). During the course of preparation of this manuscript,
another study that also reports increased Fstl1 expression in
bleomycin-treated lungs was published.59 FSTL1 has been
shown to act by directly binding to BMP, preventing binding
to its receptor complex, and thereby blocking downstream
SMAD signaling.38 In addition, FSTL1 has been shown to
bind to TGF-b1/activin complex.39 Our study reinforces the
ﬁnding that FSTL1 likely plays an important role in lungajp.amjpathol.org - The American Journal of Pathology
BMP Accessory Proteins in Lung Fibrosisﬁbrosis, with increases in the protein helping to promote the
ﬁbrotic phenotype.
In the human lung tissue, noggin, BAMBI, and FSTL1
were all detected in ﬁbrotic areas (Figure 6). There is
considerable concordance in the cellular distribution of these
BMP antagonists in human and mouse lungs. Macrophages
and bronchial epithelium express all three glycoproteins in
both species, as do the alveolar pneumocytes (Table 4).
Furthermore, in both humans and mice, ﬁbroblasts express
these three BMP antagonists in ﬁbrotic conditions. In contrast,
within the pulmonary vascular cells, only noggin is expressed
in both human and mouse endothelium, and in smooth muscle
cells only FSTL1 is expressed in both (Table 4). As is well
known, the bleomycin model does not reproduce the human
disease, and thus no honeycombing or fully developed ﬁbro-
blastic foci are seen in the mouse lungs. Nonetheless, the
extensive concordance observed suggests that the bleomycin
model will provide a useful tool to further explore the role of
these glycoproteins in ﬁbrotic lung diseases.TGF-b1eInduced Changes in Expression of BMP
Accessory Proteins
All three of these proteins are glycoproteins, so it is likely
that upon glycosylation they will stick to the cellular gly-
cocalyx close to the site of production and act in a local
context with speciﬁc functions. Thus, the exact role of these
secreted proteins needs to be explored separately in cell-
speciﬁc contexts. Because all three proteins were highly
expressed in epithelial cells, we used SAECs to look for
regulatory feedback loops that may occur in this cell type
and gain greater insight into whether it is only the initial
injury that causes increased expression of these proteins or
whether TGF-b1 also plays a role. In this study, we found
that TGF-b1 stimulation increased the expression of noggin,
BAMBI, and FSTL1, suggesting that after injury, TGF-b1
release can further drive the ﬁbrotic phenotype in this cell-
speciﬁc context.Potential Inﬂuence of Sex in Pulmonary Fibrosis
It is important to note that we used male mice in all ex-
periments and that the explanted lung tissue came from male
patients. There are sex-based differences in the severity of
pulmonary ﬁbrosis in the bleomycin mouse model, with
more severe lung disease developing in male mice.60
Therefore, when designing our experiments, we used only
male mice so that any differences seen would be due to the
effects of bleomycin and not confounded by a sex-based
effect. Furthermore, IPF is much more common in males
than in females, which is why all our human lung samples
are from male lungs. In view of this, further work will be
required to determine whether the same changes in BMP
antagonists are observed in lung ﬁbrosis in females; caution
must be exercised before extrapolating these results directly.The American Journal of Pathology - ajp.amjpathol.orgConclusions
The work presented in this study reveals for the ﬁrst time
that there is altered expression of a number of BMP
accessory proteins in the murine model of lung injury. We
also provide evidence that, for some of these proteins, post-
translational mechanisms also play an important role in
regulating expression. Clearly this may also be the case for
other proteins in the family that we have not examined. Our
results demonstrate that to fully understand the mechanisms
underlying the altered TGF-b1eBMP balance, which plays
such an important role in pulmonary ﬁbrosis, the changes in
the BMP/TGF-b accessory proteins will need to be fully
elucidated. Disturbances in these accessory proteins are
likely to play an important role in the pathogenesis of IPF.
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